Search Results

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”) announces a clinical supply agreement with BeiGene, Ltd. (NASDAQ: BGNE) (“BeiGene”) to evaluate the safety and efficacy of Bria-OTS™, BriaCell’s next generation immunotherapy, in combination with BeiGene’s anti-PD-1 antibody, tislelizumab, for the treatment of advanced heavily pretreated metastatic breast cancer.

BriaCell Therapeutics Corp. announces positive clinical efficacy data updates of its ongoing randomized Phase 2 study evaluating lead clinical candidate Bria-IMT™ in patients with advanced metastatic breast cancer.

BriaCell Therapeutics Corp. announces positive clinical data of its lead product candidate, Bria-IMT™, to be presented in one oral presentation session, two poster sessions, and one abstract on the updated clinical data of BriaCell’s randomized Phase 2 study evaluating Bria-IMT™ in patients with advanced metastatic breast cancers at the 2024 American Society of Clinical Oncology Annual Meeting taking place taking place May 31 - June 4, 2024 at McCormick Place, Chicago, IL.

BriaCell Therapeutics Corp. announces initiation of a first-in-human, Phase 1/2 study evaluating safety and efficacy of Bria-OTS™.